Rodeo Therapeutics raises $3.7M to advance 15-PGDH inhibitor therapies for IBD and post‑transplant blood recovery

Rodeo Therapeutics, a Seattle biotech developing therapies that accelerate natural tissue regeneration by inhibiting the enzyme 15-PGDH, has raised $3.7 million to pursue treatments for inflammatory bowel disease and to promote blood cell recovery after bone marrow transplants.

No comments yet.